Authors : Bharati Gawade, Rashmi Hegde
DOI : 10.18231/j.ijogr.2020.089
Volume : 7
Issue : 3
Year : 2020
Page No : 426-429
Even today, polycystic ovary syndrome (PCOS) and its management remains a challenge. The entry of
innovative products in the clinical armamentarium for PCOS management is welcome and needs to be
investigated for their efficacy and safety in Indian women suffering from PCOS. This was a multicentric
postmarketing surveillance (PMS) study done in 457 women suffering from PCOS from all over India.
92 clinicians from 35 cities participated in this study. High ovulation (91%) and conception rate (67.8%)
was reported with this study product* (fixed-dose combination of myo-inositol 550 mg, D-chiro-inositol
13.8 mg, L-methyl folate 0.1 mg, vitamin D3 400 IU and chromium picolinate 100 mcg as orange-flavoured
chewable tablets) administered as one tablet twice daily for 3 months. Reduction in body mass index (BMI),
substantial decrease in serum testosterone and hirsutism, and an increase in serum progesterone were also
reported with the study product. As a first-line management for PCOS, the fixed-dose combination of myoinositol
550 mg, D-chiro-inositol 13.8 mg, L-methyl folate 0.1 mg, vitamin D3 400 IU and chromium
picolinate 100 mcg as orange-flavoured chewable tablets, therefore, shows strong promise.
Keywords: Polycystic ovary syndrome, PCOS, Myo-inositol, D-chiro-inositol, Insulin resistance, Infertility, Anovulation, Hyperandrogenism